NEW YORK — Fujifilm has partnered with Axcelead Drug Discovery Partners to offer human induced pluripotent stem cell (iPSC)-based drug discovery services, the Japanese companies said today.
Under the terms of the deal, the firms will offer iPCSs and iPCS-derived cells from Fujifilm subsidiary Fujifilm Cellular Dynamics with Axcelead's drug discovery services, as well as customized drug evaluation and toxicity testing methods.
Additional terms were not disclosed.
Fujifilm — which acquired Madison, Wisconsin-based Cellular Dynamics in 2015 — said it will consider further collaborations in the field of drug discovery support by combining culture media and reagents from Fujifilm Irvine Scientific and from Fujifilm Wako Pure Chemical.